Vasopressin triggers senescence in K-ras transformed cells via RhoA-dependent downregulation of cyclin D1

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 1117-1125

  Forti, Fabio L ^a   Armelin, Hugo A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ARGIPRESSIN; BETA GALACTOSIDASE; CYCLIN D1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VASOPRESSIN V1 RECEPTOR;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROTECTION; CELL SURVIVAL; CELL TRANSFORMATION; DOWN REGULATION; ENZYME INDUCTION; MITOGENESIS; MOUSE; NONHUMAN; ONCOGENE K RAS; SENESCENCE; Y1 ADRENOCORTICAL MALIGNANT CELL;

ADRENAL CORTEX NEOPLASMS; ANIMALS; ARGININE VASOPRESSIN; CASPASES; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DOWN-REGULATION; GENES, RAS; GLYCOGEN SYNTHASE KINASE 3; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RHOA GTP-BINDING PROTEIN; VASOPRESSINS;

EID: 39149101466     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0154     Document Type: Article

References (27)

1. Aspenstrom P, Fransson A & Saras J 2004 Rho GTPases have diverse effects on the organization of the actin filament system. Biochemical Journal 377 327-337.
2. Barbacid M 1987 Ras genes. Annual Review of Biochemistry 56 779-827.
3. Van Biesen T, Luttrell LM, Hawes BE & Lefkowitz RJ 1996 Mitogenic signaling via G protein-coupled receptors. Endocrine Reviews 17 698-714.
4. Bos JL 1988 The ras gene family and human carcinogenesis. Mutation Research 195 255-271.
5. Coleman ML, Densham RM, Croft DR & Olson MF 2006 Stability of p21Waf1/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene 25 2708-2716.
6. Forti FL, Schwindt TT, Moraes MS, Eichler CB & Armelin HA 2002 ACTH promotion of p27(Kip1) induction in mouse Y1 adrenocortical tumor cells is dependent on both PKA activation and Akt/PKB inactivation. Biochemistry 41 10133-10140.
7. Jaffe AB & Hall A 2005 Rho GTPases: biochemistry and biology. Annual Review of Cell and Development Biology 21 247-269.
8. Kimura E & Armelin HA 1988 Role of proto-oncogene c-K-ras amplification and overexpression in the malignancy of Y1 adrenocortical tumor cells. Brazilian Journal of Medical and Biological Research 21 189-201.
9. Landis MW, Pawlyk BS, Li T, Sicinski P & Hinds PW 2006 Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9 13-22.
10. Lotfi CF & Armelin HA 2001 cfos and cjun antisense oligonucleotides block mitogenesis triggered by fibroblast growth factor-2 and ACTH in mouse Y1 adrenocortical cells. Journal of Endocrinology 168 381-389.
11. Mammoto A, Huang S, Moore K, Oh P & Ingber DE 2004 Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. Journal of Biological Chemistry 279 26323-26330.
12. Michell RH, Kirk CJ & Billah MM 1979 Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochemical Society Transactions 7 861-865.
13. Olson MF, Ashworth A & Hall A 1995 An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269 1270-1272.
14. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF & Sherr CJ 1993 Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes and Development 7 1559-1571.
15. Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P & Narumiya S 1996 Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. Journal of Biological Chemistry 271 13556-13560.
16. Resnitzky D, Gossen M, Bujard H & Reed SI 1994 Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Molecular and Cellular Biology 14 1669-1679.
17. Roy PG & Thompson AM 2006 Cyclin D1 and breast cancer. Breast 15 718-727.
18. Schwab M, Alitalo K, Varmus H, Bishop J & George D 1983 A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature 303 497-501.
19. Schwindt TT, Forti FL, Juliano MA, Juliano L & Armelin HA 2003 Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line. Biochemistry 42 2116-2121.
20. Sherr CJ 1993 Mammalian G1 cyclins. Cell 73 1059-1065.
21. Sherr CJ 2004 Principles of tumor suppression. Cell 116 235-246.
22. Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 13 1501-1512.
23. Sherr CJ & Roberts JM 2004 Living with or without cyclins and cyclin-dependent kinases. Genes and Development 18 2699-2711.
24. Thibonnier M, Bayer AL, Laethem CL, Koop DR & Simonson MS 1993 Role of eicosanoids in vasopressin-induced calcium mobilization in A7r5 vascular smooth muscle cells. American Journal of Physiology 265 E108-E114.
25. Yasumura Y, Buonassisi V & Sato G 1966 Clonal analysis of differentiated function in animal cell cultures. I. Possible correlated maintenance of differentiated function and the diploid karyotype. Cancer Research 26 529-535.
26. Yu Q, Geng Y & Sicinski P 2001 Specific protection against breast cancers by cyclin D1 ablation. Nature 411 1017-1021.
27. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stal O et al. 2006 Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9 23-32.